Polyplus acquires e-Zyvec to expand its expertise in plasmid DNA vector engineering
Strasbourg, France, February 1, 2022
Polyplus, a global leader in applied biology solutions, particularly in the field of cell and gene therapy, with products available up to medical grade (GMP), today announced the acquisition of e-Zyvec, a provider of custom DNA vector design and production services for gene therapy, bioproduction, and research. Financial details were not disclosed.
"When we launched e-Zyvec five years ago, the idea was to bring an innovative genetic engineering service to market while leveraging today's digital technology. We are delighted to join Polyplus, a leader in its field. This acquisition will enable us to accelerate the development of the e-Zyvec platform," said Sylvain Julien, president and co-founder of e-Zyvec.
"Our expertise in DNA vector design, combined with our innovative DNA molecule assembly technique, enables us to offer customized, high-value-added vectors for our clients' projects. Joining the Polyplus team is a logical step in our global growth. All members of our team will retain their current roles, providing a layer of expertise and human capital that is invaluable in today's market," said Carine Morel, CEO and co-founder of e-Zyvec.
Polyplus is evolving and growing, and this latest acquisition is an example of our strategy in action. We will continue to develop our existing portfolio, which is strong in itself, by adding complementary activities that make us a more effective and comprehensive partner for our customers, with a focus on expanding efforts to optimize process profitability for cell and gene therapy developers and manufacturers," commented Mario Philips, CEO of Polyplus.
Polyplus is a leading provider of solutions for the production of advanced biological, cellular, and gene therapies, offering products for use in research and therapy through to commercialization. Building on more than 20 years of innovative expertise in nucleic acid transfection, the solutions offered are designed to meet strict scientific and regulatory standards, from research to clinical development phases. Based in Europe and with operations in the United States and Asia, Polyplus supplies a wide and growing range of transfection reagents worldwide. Learn more at www.polyplus-transfection.com.
e-Zyvec is a French biotech startup specializing in genetic engineering, providing biopharmaceutical scientists and genetic researchers with sophisticated, tailor-made DNA vectors. The integrated e-Zyvec platform handles consulting, design, and assembly for the customized production of plasmid DNA vectors that is accurate, fast, and cost-effective for generating powerful new molecular tools. Founded in 2016, e-Zyvec offers unique innovative technology for gene therapy, bioproduction, and basic research.
https://www.e-zyvec.com
Media contact information:
Alengo Nyamay’antu, PhD
Scientific Communications Manager at Polyplus
mailto:an@polyplus-transfection.com
Direct: +1 310 232 6666
Download the press release